<MedlineCitation Status="Completed">
<MedlineID>10011833</MedlineID>
<PMID>217483</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0006-8993</ISSN>
<JournalIssue>
<Volume>160</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1979</Year>
<Month>Jan</Month>
<Day>19</Day>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Visualization of beta-adrenergic receptor sites with fluorescent beta-adrenergic blocker probes--or autofluorescent granules?</ArticleTitle>
<Pagination>
<MedlinePgn>533-8</MedlinePgn>
</Pagination>
<AuthorList>
<Author>
<LastName>Hess</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>NETHERLANDS</Country>
<MedlineTA>Brain Res</MedlineTA>
<NlmUniqueID>0045503</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Receptors, Adrenergic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Receptors, Adrenergic, beta</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>50-55-5</RegistryNumber>
<NameOfSubstance>Reserpine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>525-66-6</RegistryNumber>
<NameOfSubstance>Propranolol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Brain Chemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Brain Mapping</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Brain Stem</DescriptorName>
<QualifierName>ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Carotid Body</DescriptorName>
<QualifierName>ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Caudate Nucleus</DescriptorName>
<QualifierName>ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Cerebellum</DescriptorName>
<QualifierName>ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Cerebral Cortex</DescriptorName>
<QualifierName>ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Cytoplasmic Granules</DescriptorName>
<QualifierName MajorTopicYN="Y">ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Ganglia, Autonomic</DescriptorName>
<QualifierName>ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Microscopy, Fluorescence</DescriptorName>
<QualifierName MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Pineal Body</DescriptorName>
<QualifierName>ultrastructure</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Propranolol</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
<QualifierName MajorTopicYN="Y">analogs &#38; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Receptors, Adrenergic</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Receptors, Adrenergic, beta</DescriptorName>
<QualifierName MajorTopicYN="Y">analysis</QualifierName>
<QualifierName>drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Reserpine</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Spinal Cord</DescriptorName>
<QualifierName>ultrastructure</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
